organization · Reporting owner

Ospraie Management, Inc.

Disclosed activity across 3 companies

Tapewire entity: 40609
SEC CIK: 0001392203

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Ionetix Corp / DE /NONE · Entity 28525	10% owner	April 09, 2026	April 17, 2026
Sunshine Silver Mining & Refining CoSSMR · Entity 4369	10% owner	June 05, 2026	June 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Ionetix Corp / DE /

Report date April 09, 2026 · Filed April 17, 2026

Jointly reported with Ospraie Real Assets Fund LP, Ospraie Real Assets GP LLC, Ospraie Management, LLC, Ospraie Holding I, L.P., Anderson Dwight

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	Direct	18,206,346	Reported balance After 2026-04-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-04-09 · Other · Acquired 18,206,346 · Balance 18,206,346 F1: Received in exchange for 36,311,022 shares of the common stock of Ionetix Corporation, a privately held Delaware corporation ("Target"), in connection with the merger (such transaction, the "Merger") of JDEV Merger Subsidiary Corp. ("Merger Sub"), a wholly-owned subsidiary of JDEV Acquisition Corp. (such entity, which changed its name to Ionetix Corporation in connection with the Merger, the "Issuer"), with and into Target, pursuant to that certain Agreement and Plan of Merger and Reorganization dated as of April 9, 2026 by and among the Issuer, Target and Merger Sub. F2: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC. F3: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2028-12-14	Direct	1,316,175	Reported balance After 2026-04-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-09 · Other · Acquired 1,316,175 · Balance 1,316,175 F4: Received in the Merger in exchange for a warrant to purchase 2,625,000 shares of Target common stock at an exercise price of $1.40 per share. F2: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC. F3: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2030-04-27	Direct	537,752	Reported balance After 2026-04-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-09 · Other · Acquired 537,752 · Balance 537,752 F5: Received in the Merger in exchange for a warrant to purchase 1,072,500 shares of Target common stock at an exercise price of $1.40 per share. F2: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC. F3: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2036-04-09	Direct	3,230,558	Reported balance After 2026-04-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-09 · Other · Acquired 3,230,558 · Balance 3,230,558 F6: Received in the Merger in exchange for a warrant to purchase 6,443,076 shares of Target common stock at an exercise price of $0.01 per share. This warrant contains a provision that restricts the ability of the holder to exercise the warrant to the extent that, after giving effect to the issuance of shares of the common stock of the Issuer upon such exercise, the holder would beneficially own in excess of 19.9% of the number of outstanding shares of the Issuer's common stock. F2: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC. F3: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Received in exchange for 36,311,022 shares of the common stock of Ionetix Corporation, a privately held Delaware corporation ("Target"), in connection with the merger (such transaction, the "Merger") of JDEV Merger Subsidiary Corp. ("Merger Sub"), a wholly-owned subsidiary of JDEV Acquisition Corp. (such entity, which changed its name to Ionetix Corporation in connection with the Merger, the "Issuer"), with and into Target, pursuant to that certain Agreement and Plan of Merger and Reorganization dated as of April 9, 2026 by and among the Issuer, Target and Merger Sub.

F2: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC.

F3: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any.

F4: Received in the Merger in exchange for a warrant to purchase 2,625,000 shares of Target common stock at an exercise price of $1.40 per share.

F5: Received in the Merger in exchange for a warrant to purchase 1,072,500 shares of Target common stock at an exercise price of $1.40 per share.

F6: Received in the Merger in exchange for a warrant to purchase 6,443,076 shares of Target common stock at an exercise price of $0.01 per share. This warrant contains a provision that restricts the ability of the holder to exercise the warrant to the extent that, after giving effect to the issuance of shares of the common stock of the Issuer upon such exercise, the holder would beneficially own in excess of 19.9% of the number of outstanding shares of the Issuer's common stock.

Sunshine Silver Mining & Refining Co

Report date June 05, 2026 · Filed June 08, 2026

Jointly reported with Ospraie Real Assets Fund LP, Ospraie Real Assets GP LLC, Ospraie Management, LLC, Ospraie Holding I, L.P., Anderson Dwight

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	24,758,995	Last balance in matching sequence After 2026-06-05 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-06-05 · Other · Acquired 2,615,060 · Balance 25,314,550 F3: Ospraie Management, LLC ("OM LLC") is the investment manager of ORA Fund and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of OM LLC. Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of Ospraie Holding. F4: Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Row 2 · 2026-06-05 · Sale · Disposed 555,555 · Balance 24,758,995 F1: On June 5, 2026, in connection with the closing by Sunshine Silver Mining & Refining Company (the "Issuer") of the initial public offering of its common stock (the "IPO"), a warrant to purchase 2,615,060 shares of the common stock of the Issuer (the "Warrant"), exercisable at $2.87 per share, held by Ospraie Real Assets Fund LP ("ORA Fund"), was automatically exercised on a cashless basis, resulting in the Issuer withholding 555,555 of the warrant shares to pay the exercise price and issuing to ORA Fund the remaining 2,059,505 shares. F2: The Warrant was outstanding as of the date of the Issuer's prospectus (the "Prospectus") relating to the IPO as disclosed in the Prospectus. This filing solely relates to the cashless exercise of the Warrant, which was effected solely by the surrender to the Issuer of shares of the Issuer's common stock issuable upon exercise of the Warrant and the Issuer's cancellation thereof to pay the exercise price of the Warrant. No shares of the Issuer's common stock were sold by the reporting person(s) and the shares issued to ORA Fund upon the cashless exercise of the Warrant remain subject to the lock-up agreement that was entered into by ORA Fund in connection with the IPO and disclosed in the Prospectus. F3: Ospraie Management, LLC ("OM LLC") is the investment manager of ORA Fund and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of OM LLC. Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of Ospraie Holding. F4: Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87	Direct	0	Reported balance After 2026-06-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-05 · Other · Acquired 2,615,060 · Balance 0 F5: The warrant is exercisable until September 2, 2027; provided, that the warrant shall automatically be deemed to be exercised, on a cashless exercise basis, as to all shares of common stock of the Issuer for which it shall not previously have been exercised, upon the closing of an initial public offering by the Issuer. F3: Ospraie Management, LLC ("OM LLC") is the investment manager of ORA Fund and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of OM LLC. Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of Ospraie Holding. F4: Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On June 5, 2026, in connection with the closing by Sunshine Silver Mining & Refining Company (the "Issuer") of the initial public offering of its common stock (the "IPO"), a warrant to purchase 2,615,060 shares of the common stock of the Issuer (the "Warrant"), exercisable at $2.87 per share, held by Ospraie Real Assets Fund LP ("ORA Fund"), was automatically exercised on a cashless basis, resulting in the Issuer withholding 555,555 of the warrant shares to pay the exercise price and issuing to ORA Fund the remaining 2,059,505 shares.

F2: The Warrant was outstanding as of the date of the Issuer's prospectus (the "Prospectus") relating to the IPO as disclosed in the Prospectus. This filing solely relates to the cashless exercise of the Warrant, which was effected solely by the surrender to the Issuer of shares of the Issuer's common stock issuable upon exercise of the Warrant and the Issuer's cancellation thereof to pay the exercise price of the Warrant. No shares of the Issuer's common stock were sold by the reporting person(s) and the shares issued to ORA Fund upon the cashless exercise of the Warrant remain subject to the lock-up agreement that was entered into by ORA Fund in connection with the IPO and disclosed in the Prospectus.

F3: Ospraie Management, LLC ("OM LLC") is the investment manager of ORA Fund and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of OM LLC. Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of Ospraie Holding.

F4: Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F5: The warrant is exercisable until September 2, 2027; provided, that the warrant shall automatically be deemed to be exercised, on a cashless exercise basis, as to all shares of common stock of the Issuer for which it shall not previously have been exercised, upon the closing of an initial public offering by the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MARRONE BIO INNOVATIONS INC

Report date July 12, 2022 · Filed July 15, 2022

Jointly reported with Ospraie Ag Science LLC, Ospraie Management, LLC, Anderson Dwight, Ospraie Holding I, L.P.

Section 16 reporting ended · disclosed 2022-07-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.00001 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2022-07-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-07-12 · Other · Disposed 70,836,258 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger dated March 16, 2022 by and among the Issuer, Bioceres Crop Solutions Corp. and BCS Merger Sub, Inc. (the "Merger Agreement") in exchange for 6,233,590 ordinary shares of Bioceres Crop Solutions Corp. having a market value of $9.44 per share at closing on the effective date of the merger. F2: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie Ag Science LLC ("Ospraie LLC") and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. OAS MM, LLC may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie LLC. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and sole managing member of OAS MM, LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger dated March 16, 2022 by and among the Issuer, Bioceres Crop Solutions Corp. and BCS Merger Sub, Inc. (the "Merger Agreement") in exchange for 6,233,590 ordinary shares of Bioceres Crop Solutions Corp. having a market value of $9.44 per share at closing on the effective date of the merger.

F2: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie Ag Science LLC ("Ospraie LLC") and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. OAS MM, LLC may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie LLC. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and sole managing member of OAS MM, LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 8, 2026 23:58 UTC	Sunshine Silver Mining & Refining Co SSMR · Entity 4369	OtherWarrant (right to buy) · Derivative	2,615,060	$0.00 Strike: $2.87	$0.00	Disclosure SEC source: 0001213900-26-066476 · ownership.xml · derivative · entry 3 Ospraie Real Assets Fund LP · CIK 0001983637 · 10% owner Ospraie Real Assets GP LLC · CIK 0002126039 · 10% owner Ospraie Management, LLC · CIK 0001326533 · 10% owner Ospraie Holding I, L.P. · CIK 0001392205 · 10% owner Ospraie Management, Inc. · CIK 0001392203 · 10% owner Anderson Dwight · CIK 0001392202 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,615,060 shares Expires not disclosed F5 · derivative.expiration_date: The warrant is exercisable until September 2, 2027; provided, that the warrant shall automatically be deemed to be exercised, on a cashless exercise basis, as to all shares of common stock of the Issuer for which it shall not previously have been exercised, upon the closing of an initial public offering by the Issuer. F3 · ownership.direct: Ospraie Management, LLC ("OM LLC") is the investment manager of ORA Fund and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of OM LLC. Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of Ospraie Holding. F4 · ownership.direct: Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
June 05, 2026 Filed Jun 8, 2026 23:58 UTC	Sunshine Silver Mining & Refining Co SSMR · Entity 4369	SaleCommon Stock, par value $0.001 per share	555,555	$13.50	$7,499,992.50	Disclosure SEC source: 0001213900-26-066476 · ownership.xml · nonDerivative · entry 2 Ospraie Real Assets Fund LP · CIK 0001983637 · 10% owner Ospraie Real Assets GP LLC · CIK 0002126039 · 10% owner Ospraie Management, LLC · CIK 0001326533 · 10% owner Ospraie Holding I, L.P. · CIK 0001392205 · 10% owner Ospraie Management, Inc. · CIK 0001392203 · 10% owner Anderson Dwight · CIK 0001392202 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,758,995 F1 · kind: On June 5, 2026, in connection with the closing by Sunshine Silver Mining & Refining Company (the "Issuer") of the initial public offering of its common stock (the "IPO"), a warrant to purchase 2,615,060 shares of the common stock of the Issuer (the "Warrant"), exercisable at $2.87 per share, held by Ospraie Real Assets Fund LP ("ORA Fund"), was automatically exercised on a cashless basis, resulting in the Issuer withholding 555,555 of the warrant shares to pay the exercise price and issuing to ORA Fund the remaining 2,059,505 shares. F2 · kind: The Warrant was outstanding as of the date of the Issuer's prospectus (the "Prospectus") relating to the IPO as disclosed in the Prospectus. This filing solely relates to the cashless exercise of the Warrant, which was effected solely by the surrender to the Issuer of shares of the Issuer's common stock issuable upon exercise of the Warrant and the Issuer's cancellation thereof to pay the exercise price of the Warrant. No shares of the Issuer's common stock were sold by the reporting person(s) and the shares issued to ORA Fund upon the cashless exercise of the Warrant remain subject to the lock-up agreement that was entered into by ORA Fund in connection with the IPO and disclosed in the Prospectus. F3 · ownership.direct: Ospraie Management, LLC ("OM LLC") is the investment manager of ORA Fund and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of OM LLC. Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of Ospraie Holding. F4 · ownership.direct: Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
June 05, 2026 Filed Jun 8, 2026 23:58 UTC	Sunshine Silver Mining & Refining Co SSMR · Entity 4369	OtherCommon Stock, par value $0.001 per share	2,615,060	$2.87	$7,505,222.20	Disclosure SEC source: 0001213900-26-066476 · ownership.xml · nonDerivative · entry 1 Ospraie Real Assets Fund LP · CIK 0001983637 · 10% owner Ospraie Real Assets GP LLC · CIK 0002126039 · 10% owner Ospraie Management, LLC · CIK 0001326533 · 10% owner Ospraie Holding I, L.P. · CIK 0001392205 · 10% owner Ospraie Management, Inc. · CIK 0001392203 · 10% owner Anderson Dwight · CIK 0001392202 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,314,550 F3 · ownership.direct: Ospraie Management, LLC ("OM LLC") is the investment manager of ORA Fund and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of OM LLC. Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of Ospraie Holding. F4 · ownership.direct: Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the securities of the Issuer held by ORA Fund as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 09, 2026 Filed Apr 17, 2026 01:09 UTC	Ionetix Corp / DE / NONE · Entity 28525	OtherWarrant · Derivative	3,230,558	Not disclosed Strike: $0.02	Not disclosed	Disclosure SEC source: 0001213900-26-044849 · ownership.xml · derivative · entry 4 Ospraie Real Assets Fund LP · CIK 0001983637 · 10% owner Ospraie Real Assets GP LLC · CIK 0002126039 · 10% owner Ospraie Management, LLC · CIK 0001326533 · 10% owner Ospraie Holding I, L.P. · CIK 0001392205 · 10% owner Ospraie Management, Inc. · CIK 0001392203 · 10% owner Anderson Dwight · CIK 0001392202 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,230,558 Underlying: Common Stock · 3,230,558 shares Expires 2036-04-09 F6 · price: Received in the Merger in exchange for a warrant to purchase 6,443,076 shares of Target common stock at an exercise price of $0.01 per share. This warrant contains a provision that restricts the ability of the holder to exercise the warrant to the extent that, after giving effect to the issuance of shares of the common stock of the Issuer upon such exercise, the holder would beneficially own in excess of 19.9% of the number of outstanding shares of the Issuer's common stock. F2 · ownership.direct: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC. F3 · ownership.direct: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 09, 2026 Filed Apr 17, 2026 01:09 UTC	Ionetix Corp / DE / NONE · Entity 28525	OtherWarrant · Derivative	537,752	Not disclosed Strike: $2.79	Not disclosed	Disclosure SEC source: 0001213900-26-044849 · ownership.xml · derivative · entry 3 Ospraie Real Assets Fund LP · CIK 0001983637 · 10% owner Ospraie Real Assets GP LLC · CIK 0002126039 · 10% owner Ospraie Management, LLC · CIK 0001326533 · 10% owner Ospraie Holding I, L.P. · CIK 0001392205 · 10% owner Ospraie Management, Inc. · CIK 0001392203 · 10% owner Anderson Dwight · CIK 0001392202 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537,752 Underlying: Common Stock · 537,752 shares Expires 2030-04-27 F5 · price: Received in the Merger in exchange for a warrant to purchase 1,072,500 shares of Target common stock at an exercise price of $1.40 per share. F2 · ownership.direct: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC. F3 · ownership.direct: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 09, 2026 Filed Apr 17, 2026 01:09 UTC	Ionetix Corp / DE / NONE · Entity 28525	OtherWarrant · Derivative	1,316,175	Not disclosed Strike: $2.79	Not disclosed	Disclosure SEC source: 0001213900-26-044849 · ownership.xml · derivative · entry 2 Ospraie Real Assets Fund LP · CIK 0001983637 · 10% owner Ospraie Real Assets GP LLC · CIK 0002126039 · 10% owner Ospraie Management, LLC · CIK 0001326533 · 10% owner Ospraie Holding I, L.P. · CIK 0001392205 · 10% owner Ospraie Management, Inc. · CIK 0001392203 · 10% owner Anderson Dwight · CIK 0001392202 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,316,175 Underlying: Common Stock · 1,316,175 shares Expires 2028-12-14 F4 · price: Received in the Merger in exchange for a warrant to purchase 2,625,000 shares of Target common stock at an exercise price of $1.40 per share. F2 · ownership.direct: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC. F3 · ownership.direct: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 09, 2026 Filed Apr 17, 2026 01:09 UTC	Ionetix Corp / DE / NONE · Entity 28525	OtherCommon Stock, par value $0.0001 per share	18,206,346	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-26-044849 · ownership.xml · nonDerivative · entry 1 Ospraie Real Assets Fund LP · CIK 0001983637 · 10% owner Ospraie Real Assets GP LLC · CIK 0002126039 · 10% owner Ospraie Management, LLC · CIK 0001326533 · 10% owner Ospraie Holding I, L.P. · CIK 0001392205 · 10% owner Ospraie Management, Inc. · CIK 0001392203 · 10% owner Anderson Dwight · CIK 0001392202 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,206,346 F1 · price: Received in exchange for 36,311,022 shares of the common stock of Ionetix Corporation, a privately held Delaware corporation ("Target"), in connection with the merger (such transaction, the "Merger") of JDEV Merger Subsidiary Corp. ("Merger Sub"), a wholly-owned subsidiary of JDEV Acquisition Corp. (such entity, which changed its name to Ionetix Corporation in connection with the Merger, the "Issuer"), with and into Target, pursuant to that certain Agreement and Plan of Merger and Reorganization dated as of April 9, 2026 by and among the Issuer, Target and Merger Sub. F2 · ownership.direct: Ospraie Management, LLC ("OM LLC") is the investment manager of Ospraie Real Assets Fund LP ("ORA Fund") and has been delegated voting and investment power and thus beneficial ownership of the securities of the Issuer held by ORA Fund (such securities, the "Issuer Securities"). Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the Issuer Securities as the managing member of OM LLC. F3 · ownership.direct: Ospraie Management, Inc. ("OM Inc.") may be deemed to beneficially own the Issuer Securities as the general partner of Ospraie Holding. Ospraie Real Assets GP LLC ("Ospraie GP") may be deemed to beneficially own the Issuer Securities as the general partner of ORA Fund. Dwight Anderson may be deemed to beneficially own the Issuer Securities as the managing member of Ospraie GP and as the sole owner of OM Inc. Each reporting person disclaims beneficial ownership of the Issuer Securities except to the extent of his or its pecuniary interest therein, if any. Read SEC document
July 12, 2022 Filed Jul 15, 2022 09:09 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	OtherCommon Stock, $0.00001 par value	70,836,258	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-22-039487 · ownership.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger dated March 16, 2022 by and among the Issuer, Bioceres Crop Solutions Corp. and BCS Merger Sub, Inc. (the "Merger Agreement") in exchange for 6,233,590 ordinary shares of Bioceres Crop Solutions Corp. having a market value of $9.44 per share at closing on the effective date of the merger. F2 · ownership.direct: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie Ag Science LLC ("Ospraie LLC") and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. OAS MM, LLC may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie LLC. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and sole managing member of OAS MM, LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 15, 2021 Filed Dec 17, 2021 16:10 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	3,553,583	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-21-048765 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,553,583 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On December 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 3,553,583 shares of Issuer Common Stock underlying such warrants. F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · kind: (Continued from Footnot 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On December 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 3,553,583 shares of Issuer Common Stock underlying such warrants. F2 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · price: (Continued from Footnot 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 15, 2021 Filed Dec 17, 2021 16:10 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	3,553,583	$0.75	$2,665,187.25	Disclosure SEC source: 0000899243-21-048765 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,836,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On December 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 3,553,583 shares of Issuer Common Stock underlying such warrants. F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · kind: (Continued from Footnot 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
March 15, 2021 Filed Mar 16, 2021 11:51 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	4,264,299	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-21-011876 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,264,299 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 4,264,299 shares of Issuer Common Stock underlying such warrants. F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · kind: (continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On March 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 4,264,299 shares of Issuer Common Stock underlying such warrants. F2 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · price: (continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
March 15, 2021 Filed Mar 16, 2021 11:51 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	4,264,299	$0.75	$3,198,224.25	Disclosure SEC source: 0000899243-21-011876 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,282,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 4,264,299 shares of Issuer Common Stock underlying such warrants. F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · kind: (continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 15, 2020 Filed Dec 17, 2020 14:39 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	9,476,221	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-20-034269 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,476,221 shares Expires 2020-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On December 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 9,476,221 shares of Issuer Common Stock underlying such warrants. F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · kind: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On December 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 9,476,221 shares of Issuer Common Stock underlying such warrants. F2 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · price: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
December 15, 2020 Filed Dec 17, 2020 14:39 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	9,476,221	$0.75	$7,107,165.75	Disclosure SEC source: 0000899243-20-034269 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,018,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On December 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 9,476,221 shares of Issuer Common Stock underlying such warrants. F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · kind: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
September 15, 2020 Filed Oct 13, 2020 16:25 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	1,974,213	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-20-028006 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,974,213 shares Expires 2020-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 1,974,213 shares of Issuer Common Stock underlying such warrants. F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · kind: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On September 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 1,974,213 shares of Issuer Common Stock underlying such warrants. F2 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · price: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
September 15, 2020 Filed Oct 13, 2020 16:25 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	1,974,213	$0.75	$1,480,659.75	Disclosure SEC source: 0000899243-20-028006 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,542,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 1,974,213 shares of Issuer Common Stock underlying such warrants. F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F3 · kind: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
May 01, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	2,467,766	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 12 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,467,766 shares Expires 2020-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
May 01, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	2,467,766	$0.75	$1,850,824.50	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,567,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	GrantWarrant · Derivative	3,553,583	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 11 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,553,583 Underlying: Common Stock · 3,553,583 shares Expires 2021-12-15 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	GrantWarrant · Derivative	4,264,299	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 10 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,264,299 Underlying: Common Stock · 4,264,299 shares Expires 2021-03-15 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	GrantWarrant · Derivative	9,476,221	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 9 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,476,221 Underlying: Common Stock · 9,476,221 shares Expires 2020-12-15 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	GrantWarrant · Derivative	1,974,213	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 8 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,974,213 Underlying: Common Stock · 1,974,213 shares Expires 2020-09-15 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	GrantWarrant · Derivative	2,467,766	Not disclosed Strike: $0.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 7 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,467,766 Underlying: Common Stock · 2,467,766 shares Expires 2020-05-01 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerWarrant · Derivative	5,027,325	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 6 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,027,325 shares Expires 2023-01-01 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerWarrant · Derivative	1,675,771	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 5 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,675,771 shares Expires 2023-01-01 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerWarrant · Derivative	3,351,542	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 4 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,351,542 shares Expires 2023-01-01 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerWarrant · Derivative	8,378,871	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 3 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,378,871 shares Expires 2023-01-01 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share. Read SEC document
April 29, 2020 Filed May 1, 2020 17:11 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Disposition to issuerWarrant · Derivative	12,233,158	Not disclosed Strike: $1.00	Not disclosed	Disclosure SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,233,158 shares Expires 2021-12-31 F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share. F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors. F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding. F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share. Read SEC document
March 04, 2020 Filed Mar 6, 2020 15:01 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	5,027,325	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0000899243-20-007399 · doc4.xml · derivative · entry 3 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,027,325 Underlying: Common Stock · 5,027,325 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. F2 · kind: (Continued from Footnote 1) Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants. F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · derivative.exercise_date: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants. Read SEC document
March 04, 2020 Filed Mar 6, 2020 15:01 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	5,027,325	Not disclosed Strike: $1.00	Not disclosed	Disclosure SEC source: 0000899243-20-007399 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,233,158 Underlying: Common Stock · 5,027,325 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. F2 · kind: (Continued from Footnote 1) Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants. F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · derivative.exercise_date: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants. Read SEC document
March 04, 2020 Filed Mar 6, 2020 15:01 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	5,027,325	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-007399 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,100,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. F2 · kind: (Continued from Footnote 1) Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants. Read SEC document
December 30, 2019 Filed Jan 2, 2020 15:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	1,675,771	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0000899243-20-000043 · doc4.xml · derivative · entry 3 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,675,771 Underlying: Common Stock · 1,675,771 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from Footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. F4 · kind: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. F4 · price: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants. F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. F4 · derivative.exercise_date: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants. Read SEC document
December 30, 2019 Filed Jan 2, 2020 15:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	1,675,771	Not disclosed Strike: $1.00	Not disclosed	Disclosure SEC source: 0000899243-20-000043 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,260,483 Underlying: Common Stock · 1,675,771 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from Footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. F4 · kind: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. F4 · price: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants. F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. F4 · derivative.exercise_date: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants. Read SEC document
December 30, 2019 Filed Jan 2, 2020 15:19 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	1,675,771	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-000043 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,072,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from Footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. F4 · kind: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. F4 · price: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants. Read SEC document
December 18, 2019 Filed Dec 20, 2019 15:04 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	3,351,542	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0000899243-19-029736 · doc4.xml · derivative · entry 3 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,351,542 Underlying: Common Stock · 3,351,542 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · derivative.exercise_date: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants Read SEC document
December 18, 2019 Filed Dec 20, 2019 15:04 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	3,351,542	Not disclosed Strike: $1.00	Not disclosed	Disclosure SEC source: 0000899243-19-029736 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,936,254 Underlying: Common Stock · 3,351,542 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · derivative.exercise_date: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants Read SEC document
December 18, 2019 Filed Dec 20, 2019 15:04 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	3,351,542	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-029736 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants Read SEC document
September 04, 2019 Filed Sep 5, 2019 17:41 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	8,378,871	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0000899243-19-022863 · doc4.xml · derivative · entry 3 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,378,871 Underlying: Common Stock · 8,378,871 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants. F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · derivative.exercise_date: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants. Read SEC document
September 04, 2019 Filed Sep 5, 2019 17:41 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionWarrant · Derivative	8,378,871	Not disclosed Strike: $1.00	Not disclosed	Disclosure SEC source: 0000899243-19-022863 · doc4.xml · derivative · entry 2 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,287,796 Underlying: Common Stock · 8,378,871 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants. F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · derivative.exercise_date: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants. Read SEC document
September 04, 2019 Filed Sep 5, 2019 17:41 UTC	MARRONE BIO INNOVATIONS INC MBII · Entity 125354	Exercise / conversionCommon Stock, $0.00001 par value	8,378,871	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-022863 · doc4.xml · nonDerivative · entry 1 Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks) Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks) Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks) Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks) Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,045,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants. F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.